Cascadian Therapeutics (Nasdaq: CASC) announced the presentation of clinical activity of tucatinib, its investigational, highly selective small molecule HER2 inhibitor ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE